AbbVie has begun a Phase III trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy. The randomized, placebo-controlled, double-blind trial will recruit approximately 620 patients who will be randomized to one of three ar...